Related Experiment Video
Updated: Apr 3, 2026
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
7.2K
Treating Heart Failure with Preserved Ejection Fraction: A Challenge for Clinicians.
1Professor and Vice Chair, Department of Pharmacy Practice, University of Kansas Medical Center , Mailstop 4047, 3901 Rainbow Boulevard, Kansas City, KS 66160.
Hospital Pharmacy
|September 26, 2015
Summary
Heart failure with preserved ejection fraction (HFpEF) is rising, posing challenges for treatment. Current therapies effective for systolic heart failure are less successful in HFpEF patients, necessitating new drug development.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Cardiovascular disease trends show a decline, yet heart failure (HF) incidence is increasing.
- Heart failure with preserved ejection fraction (HFpEF) is a prevalent condition, particularly in patients with multiple comorbidities.
- HFpEF presents significant clinical challenges due to poorly understood mechanisms and debated treatment strategies.
Purpose of the Study:
- To provide an overview of current drug therapies for HFpEF.
- To highlight the limitations of existing treatments in HFpEF.
- To introduce novel therapeutic agents currently under investigation for HFpEF.
Main Methods:
- Review of existing literature on HFpEF pharmacotherapy.
- Analysis of clinical trial data for established and emerging HFpEF treatments.
- Discussion of pharmacological mechanisms relevant to HFpEF pathophysiology.
Main Results:
- Standard HF therapies like angiotensin and beta-receptor blockers show limited efficacy in HFpEF.
- The pathophysiology of HFpEF differs from systolic HF, impacting treatment response.
- Several new drug classes are being investigated for their potential to treat HFpEF.
Conclusions:
- Effective pharmacotherapy for HFpEF remains a critical unmet need.
- Understanding HFpEF mechanisms is crucial for developing targeted treatments.
- Ongoing research into novel agents offers hope for improved HFpEF management.
Related Concept Videos
01:17Pathophysiology of Heart Failure
4.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.6K
01:30Heart Failure IV: Classification and Diagnostic Evaluation
602
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
602
01:29Heart Failure II: Pathophysiology
1.4K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
01:27Heart Failure I: Introduction
1.3K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.3K
01:26Heart Failure III: Clinical Manifestations
879
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
879
01:30Heart Failure V: Medical Management
544
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
544